The third stop of the national "Boya Hui - Evidence China Tour" public lecture series, themed "Real-World Pharmacoeconomics Research," was successfully held on August 7 at the West China Campus of Sichuan University. Continuing the academic initiative of the public welfare tour, the event focused on the challenges, pain points, and innovative pathways of integrating real-world research with pharmacoeconomics. Nearly 100 representatives gathered in Chengdu, including scholars from the health economics field, clinical and pharmacy experts from top-tier hospitals, senior pharmacoeconomics researchers, heads of market access and R&D from leading pharmaceutical companies, industry associations, scientific research institutions, and industrial service organizations. They explored new pathways for the standardized, systematic, and industrialized development of localized real-world research.

The conference was chaired by Dr. Zhang Shiqin, who also served as the opening host. As the initiator and organizer of the "Boya Hui - Evidence China Tour" national lecture series, Dr. Zhang first extended a warm welcome to all attending experts and colleagues, and expressed sincere gratitude to the West China School of Public Health of Sichuan University for its support of the Chengdu event. He noted that while the volume of clinical real-world data in China is continuously expanding, raw data does not equate to decision-making evidence. He emphasized that the core challenge and industry practice difficulty at this stage of tripartite healthcare reform involves leveraging pharmacoeconomic tools and scientific, standardized research designs to transform scattered clinical real-world information into complete, credible, actionable, and trustworthy decision-making evidence. He stressed that the series of public welfare lectures will steadfastly uphold the original intent of value exploration, rooted in the actual development of the industry to deeply cultivate the field of real-world research. Real-world research must be based on clinical realities, balancing the sustainability of medical insurance funds, patient accessibility to medication, and the innovative development of the pharmaceutical industry. It must continuously break down barriers between data, research, policy, and industry to build a mutually beneficial and value-co-created industry ecosystem.

Dean Pan Jie of the West China School of Public Health, Sichuan University, delivered a welcome address on behalf of the university. He highly commended the academic orientation and industry value of the conference, pointing out that real-world data is a valuable resource in the medical and health field. Only by relying on scientific health economics research methods can data be quantitatively organized, standardized, transformed, and effectively utilized, thereby truly releasing its clinical and policy value. He expressed that the long-term development of real-world research requires the collaborative efforts of university scholars, clinical experts, medical insurance administrators, and industry colleagues. He looked forward to the open and deep discussions among the multi-disciplinary experts present, sharing frontline practical experience, colliding with cutting-edge academic thought, and solidifying actionable and replicable research results to support the high-quality integration of real-world research and pharmacoeconomics in the Southwest region.

Professor Liu Guoen from the Peking University Global Health and Development Institute delivered the opening keynote address. Professor Liu first highly praised the disciplinary construction achievements and development momentum of the West China School of Public Health. From the macro perspective of the pharmaceutical industry, he explained that real-world research is a crucial supplement to randomized controlled trials. Against the backdrop of ongoing national medical insurance policy reforms, real-world evidence has been deeply integrated into core scenarios such as drug value assessment, medical insurance formulary access, and clinical rational drug use, becoming a key support for the high-quality development of the pharmaceutical industry. He stated that through the "Boya Hui" national public welfare lecture tour, the popularization and implementation of health economics concepts and methods will be effectively promoted. He expressed the hope that the Chengdu stop, through diverse formats like expert presentations, case studies, and roundtable discussions, would facilitate the exchange of cutting-edge research paradigms, deeply explore the value of medical data, and identify policy implementation directions, providing high-quality references for the standardized development of real-world research nationwide.

Minister Huang Yanli from the Science and Information Department of the Wuhou District Hospital Management Service Center in Chengdu gave a presentation titled "Building a Real-World Data System and Exploring Value: Empowering Primary Healthcare Services." Combining her frontline experience in primary healthcare management, she systematically outlined the classification standards, application scenarios, and accumulation mechanisms of real-world medical data at the grassroots level. She summarized the pathways for the sustainable accumulation and standardized application of data and proposed the core goal of applying real-world data: to drive the iterative upgrade of traditional healthcare service systems and build a new human-centered Primary Care Accountable Care (PCAC) model, offering fresh ideas for the digital and refined development of primary healthcare.

Researcher Tan Jing from the China Evidence-Based Medicine Center at West China Hospital of Sichuan University delivered a special report titled "Real-World Data-Driven Clinical Value Assessment of Modern Traditional Chinese Medicine." Focusing on the innovation of real-world data science and clinical research methodologies, she introduced the core technology for establishing real-world cohorts, a pioneering effort in China. By aggregating real-world clinical data from the target population across their entire lifecycles, this approach overcomes the limitations of traditional clinical trials in evaluating the efficacy of modern traditional Chinese medicine. She also deeply analyzed the three core challenges in modern traditional Chinese medicine real-world research鈥攄ata sources, efficacy validation, and safety assessment鈥攁nd proposed targeted scientific solutions, providing important references for the implementation of real-world research, the exploration of clinical value, and the construction of a scientific evaluation system in the field of traditional Chinese medicine. The two insightful reports, characterized by their rich content and rigorous logic, drew repeated applause from the audience.

The core roundtable discussion of the conference was entirely moderated by Professor Hu Ming from the West China School of Pharmacy, Sichuan University. Centered on three key topics鈥斺淪tandardized Hospital Data Construction, Science-Based Transformation from RWD to RWE, and Evidence Planning for the Full Lifecycle of Innovative Drugs鈥攎ultiple experts from top-tier hospitals, university research institutes, medical insurance administration departments, and leading pharmaceutical companies engaged in a multi-dimensional, in-depth debate, generating many new ideas and solutions for the industry.

Director Wang Xiaodong from West China Hospital of Sichuan University, representing one of the 79 national pilot hospitals for real-world data, spoke first. He introduced that the hospital has established a dedicated department for real-world data research and improved its internal research system. However, he also acknowledged the core pain points currently facing the industry: differences in understanding data standards, quality requirements, and application logic among health authorities, medical insurance departments, and healthcare institutions. The lack of a nationally unified, standardized data quality standard, and the still-incomplete methodology and application pathways for real-world evidence review of drugs, are major challenges for pilot hospitals in advancing research implementation.

From the perspective of university research, Professor Xu Cheng deeply analyzed the difficulties of data application in tripartite healthcare coordination. He pointed out that while university research is often based on a macro-level societal perspective, the healthcare, medical insurance, and pharmaceutical sectors have different positions and core demands. Significant differences in data collection standards, application scenarios, and evaluation dimensions lead to substantial difficulties in cross-sector data collaboration and result sharing, hindering the efficient implementation and application of real-world evidence.

Director Wang Yixin from the Medical Insurance Department of Sichuan Cancer Hospital, innovatively proposed a dual value system for real-world evidence from the perspective of medical insurance decision-making: "relative value" and "absolute value." Relative value focuses on comparing a drug's clinical and economic advantages against competitors for the same indication, while absolute value emphasizes the drug's long-term societal health benefits and public health value. He emphasized that as medical technology evolves and disciplines develop, a drug's value is in a state of dynamic change. Therefore, real-world research must adhere to an objective, long-term evaluation concept to meet the needs of precise medical insurance decision-making.

Team Leader Wang Bihua from the Medical Insurance Department of Sichuan Provincial People's Hospital focused on the construction of industry standards. He stated that the core development goal of real-world research is to build a unified and standardized industry standard system. In the future, hierarchical and classified management of in-hospital data, precise adaptation to clinical scenarios, and differentiated provision of evidence for medical insurance will become key points for the implementation of real-world research in medical institutions.

Dr. Wang Lingdi, Chief Technology Officer at Boji Medical, shared cutting-edge concepts from the pharmaceutical R&D perspective. She proposed that drug value design should be planned upfront, integrating pharmacoeconomic thinking and methods early in the clinical R&D phase, based on clinical needs, clinical goals, and industrial positioning. This goal-oriented approach to standardized research design can systematically address core issues in the full lifecycle of a drug, including value assessment, clinical application, and market access, achieving deep linkage between R&D, clinical practice, medical insurance, and industry.

At the conclusion of the discussion, Professor Hu Ming systematically summarized the viewpoints of all panelists. She noted that the different positions and demands of the various entities in the tripartite healthcare system lead to significant differences in their needs for data acquisition, quality control standards, and application scenarios. Real-world research must simultaneously consider clinical authenticity, medical insurance sustainability, patient accessibility, and industrial innovation. This multi-dimensional expert debate effectively broke down communication barriers in data, research, policy, and industry, providing rich references for industry practice. She also fully recognized the academic value and industry empowerment role of the "Boya Hui - Evidence China Tour" lecture series on real-world pharmacoeconomics research, and proposed that "applied scholars" are a crucial force driving industry progress. She expressed hope for more academic research to be implemented in clinical practice and industry, continuously supporting the integrated and innovative development of real-world research and pharmacoeconomics in the Southwest region.

This event brought together professional forces from hospital medical insurance departments, clinical departments of top-tier tertiary hospitals, university research institutes, and pharmaceutical industry R&D and marketing departments, aiming to break down the long-standing communication barriers between policy, clinical practice, academia, and industry, and to build a high-quality evidence-based exchange bridge in the Southwest region. The entire conference featured in-depth discussions on common industry pain points, including real-world research data governance, the construction of real-world data, the rules for medical insurance review and acceptance, and the integration of RWS with pharmacoeconomics. Experts from various fields expressed their views and engaged in thorough debate, providing food for thought and reference for medical institutions and pharmaceutical companies in Chengdu and the Southwest region to conduct standardized real-world research and build a complete drug value evaluation system. After the successful conclusion of the "Boya Hui - Evidence China Tour" symposium on "Real-World Pharmacoeconomics Research" in Wuhan, Kunming, and Chengdu, the national series of public welfare lecture tours will continue unabated, delving deeper into the integrated application of real-world research and pharmacoeconomics, building a national high-level academic exchange platform, empowering evidence-based practice with data, supporting tripartite healthcare reform with professional expertise, and continuously promoting the high-quality, standardized, and long-term development of the domestic pharmaceutical industry.